An oral formulation of cilostazol nanoparticles enhances intestinal drug absorption in rats

Yoshioka,Chiaki; Ito,Yoshimasa; Nagai,Noriaki

doi:10.3892/etm.2017.5373

An oral formulation of cilostazol nanoparticles enhances intestinal drug absorption in rats

Authors:
- Chiaki Yoshioka
- Yoshimasa Ito
- Noriaki Nagai
View Affiliations

Affiliations: Faculty of Pharmacy, Kindai University, Higashi‑Osaka, Osaka 577‑8502, Japan
Published online on: October 24, 2017 https://doi.org/10.3892/etm.2017.5373
Pages: 454-460

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cilostazol (CLZ) is an anti‑platelet agent that is generally used after the onset of cerebral infarction. However, CLZ is a poorly water‑soluble drug and a strategy for increasing its bioavailability is required. In the present study, novel oral formulations were designed containing CLZ solid nanoparticles to improve bioavailability. The present study investigated the therapeutic effect of the oral formulations containing CLZ nanoparticles on ischemic stroke using a cerebral ischemia/reperfusion‑induced injury model (MCAO/reperfusion mice). The oral formulation containing CLZ nanoparticles (CLZ/Rnano tablet) was prepared using a combination of recrystallization and ball milling with the following ingredients: CLZ, docusate sodium, methylcellulose, 2‑hydoxypropyl‑β‑cyclodextrin, gum arabic, polyvinylpyrrolidone, and mannitol. The particle size after re‑dispersion of the CLZ/Rnano tablet was 64±47 nm (mean ± standard deviation). The CLZ areas under the concentration‑time curve (AUC) and mean residence time (MRT) in rats that were administered CLZ/Rnano tablets were significantly greater compared with those in rats that were administered CLZ/Rmicro tablets. Results indicated, the AUC after administration of CLZ/Rnano tablets was 3.1‑fold higher compared with that after administration of the commercially available CLZ OD tablet. In addition, oral administration with CLZ/Rnano tablets ameliorated neurological deﬁcits caused by ischemic stroke in MCAO/reperfusion mice. It is possible that the oral formulation containing CLZ nanoparticles will be useful for the treatment of patients with ischemic stroke and that these findings will provide significant information that can be used to improve the drug with low bioavailability.

View Figures

View References

1	Kimura Y, Tani T, Kanbe T and Watanabe K: Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 35:1144–1149. 1985.PubMed/NCBI
2	Kanbayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M and Czerwiec F: Cilostazol as a unique antithrombotic agent. Curr Pharm Des. 9:2289–2302. 2003. View Article : Google Scholar : PubMed/NCBI
3	Bramer SL and Forbes WP: Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin Pharmacokinet. 37 Suppl 2:S13–S23. 1999. View Article : Google Scholar
4	Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K and Kimura T: Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 111:56–64. 2006. View Article : Google Scholar : PubMed/NCBI
5	Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K and Kimura T: In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. J Control Release. 130:29–37. 2008. View Article : Google Scholar : PubMed/NCBI
6	Lee JH, Park SY, Shin YW, Hong KW, Kim CD, Sung SM, Kim KY and Lee WS: Neuroprotection by CLZ, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res. 1082:182–191. 2006. View Article : Google Scholar : PubMed/NCBI
7	Rasenack N and Müller BW: Micron-size drug particles: Common and novel micronization techniques. Pharm Dev Technol. 9:1–13. 2004. View Article : Google Scholar : PubMed/NCBI
8	Murakami H, Kobayashi M, Takeuchi H and Kawashima Y: Further application of a modified spontaneous emulsification solvent diffusion method to various types of PLGA and PLA polymers for preparation of nanoparticles. Powder Technol. 107:137–143. 2000. View Article : Google Scholar
9	Kawashima Y: Design of poly (lactic-co-glycolic acid) (PLGA) nanosphere for developing to DDS. J Pharm Sci Technol Jpn. 66:224–238. 2006.
10	Sha S, Vong LB, Chonpathompikunlert P, Yoshitomi T, Matsui H and Nagasaki Y: Suppression of NSAID-induced small intestinal inflammation by orally administered redox nanoparticles. Biomaterials. 34:8393–8400. 2013. View Article : Google Scholar : PubMed/NCBI
11	Igarashi R, Takenaga M, Takeuchi J, Kitagawa A, Matsumoto K and Mizushima Y: Marked hypotensive and blood flow-increasing effects of a new lipo-PGE(1) (lipo-AS013) due to vascular wall targeting. J Control Release. 71:157–164. 2001. View Article : Google Scholar : PubMed/NCBI
12	Kataoka K, Harada A and Nagasaki Y: Block copolymer micelles for drug delivery design, characterization and biological significance. Adv Drug Deliv Rev. 47:113–131. 2001. View Article : Google Scholar : PubMed/NCBI
13	Nagai N, Nakazawa Y, Ito Y, Kanai K, Okamoto N and Shimomura Y: A nanoparticle-based ophthalmic formulation of dexamethasone enhances corneal permeability of the drug and prolongs its corneal residence time. Biol Pharm Bull. 40:1055–1062. 2017. View Article : Google Scholar : PubMed/NCBI
14	Nagai N, Ito Y, Okamoto N and Shimomura Y: Size effect of rebamipide ophthalmic nanodispersions on its therapeutic efficacy for corneal wound healing. Exp Eye Res. 151:47–53. 2016. View Article : Google Scholar : PubMed/NCBI
15	Nagai N, Yoshioka C, Ito Y, Funakami Y, Nishikawa H and Kawabata A: Intravenous administration of cilostazol nanoparticles ameliorates acute ischemic stroke in a cerebral ischemia/reperfusion-induced injury model. Int J Mol Sci. 16:29329–29344. 2015. View Article : Google Scholar : PubMed/NCBI
16	Nagai N, Yoshioka C, Tanabe W, Tanino T, Ito Y, Okamoto N and Shimomura Y: Effects of ophthalmic formulations containing cilostazol nanoparticles on retinal vasoconstriction in rats injected with endothelin-1. Pharm Anal Acta. 6:42015.
17	Nagai N and Ito Y: Effect of solid nanoparticle of indomethacin on therapy for rheumatoid arthritis in adjuvant-induced arthritis rat. Biol Pharm Bull. 37:1109–1118. 2014. View Article : Google Scholar : PubMed/NCBI
18	Nagai N, Ito Y, Okamoto N and Shimomura Y: A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. Toxicology. 319:53–62. 2014. View Article : Google Scholar : PubMed/NCBI
19	Choi M, Na K, Kim J, Sakamoto Y, Terasaki O and Ryoo R: Stable single-unit-cell nanosheets of zeolite MFI as active and long-lived catalysts. Nature. 461:246–249. 2009. View Article : Google Scholar : PubMed/NCBI
20	Mintova S, Olson NH, Valtchev V and Bein T: Mechanism of zeolite A nanocrystal growth from colloids at room temperature. Science. 283:958–960. 1999. View Article : Google Scholar : PubMed/NCBI
21	Tosheva L and Valtchev VP: Nanozeolites: Synthesis, crytallisation mechanism and applications. Chem Mater. 17:24942005. View Article : Google Scholar
22	Nagai N and Ito Y: Delay of cataract development in the Shumiya cataract rat by water containing enhanced concentrations of magnesium and calcium. Curr Eye Res. 32:439–445. 2007. View Article : Google Scholar : PubMed/NCBI
23	Stowell GW, Behme RJ, Denton SM, Pfeiffer I, Sancilio FD, Whittall LB and Whittle RR: Thermally-prepared polymorphic forms of cilostazol. J Pharm Sci. 91:2481–2488. 2002. View Article : Google Scholar : PubMed/NCBI
24	Whittall LB, Whittle RR and Stowell GW: Polymorphic forms of cilostazol. Acta Cryst C. 58:0525–0527. 2002. View Article : Google Scholar
25	Kasahara Y, Nakagomi T, Matsuyama T, Stern D and Taguchi A: Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. Stroke. 43:499–506. 2012. View Article : Google Scholar : PubMed/NCBI